Search
Mostrar filtros
Add filters:
Use filters to refine the search results.
Results 1-10 of 72 (Search time: 0.041 seconds).
| Issue Date | Title | Author(s) |
|---|---|---|
| 2012 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | SCHMOLL, H. J.; CUTSEM, E. Van; STEIN, A.; VALENTINI, V.; GLIMELIUS, B.; HAUSTERMANS, K.; NORDLINGER, B.; VELDE, C. J. van de; BALMANA, J.; REGULA, J.; NAGTEGAAL, I. D.; BEETS-TAN, R. G.; ARNOLD, D.; CIARDIELLO, F.; HOFF, P.; KERR, D.; KOEHNE, C. H.; LABIANCA, R.; PRICE, T.; SCHEITHAUER, W.; SOBRERO, A.; TABERNERO, J.; ADERKA, D.; BARROSO, S.; BODOKY, G.; DOUILLARD, J. Y.; GHAZALY, H. El; GALLARDO, J.; GARIN, A.; GLYNNE-JONES, R.; JORDAN, K.; MESHCHERYAKOV, A.; PAPAMICHAIL, D.; PFEIFFER, P.; SOUGLAKOS, I.; TURHAL, S.; CERVANTES, A. |
| 2013 | Non-inferiority cancer clinical trials: scope and purposes underlying their design | RIECHELMANN, R. P.; ALEX, A.; CRUZ, L.; BARIANI, G. M.; HOFF, P. M. |
| 2016 | Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1-expressing NSCLC: Updated outcomes of KEYNOTE-010 | HERBST, R. S.; BAAS, P.; KIM, D-W.; FELIP, E.; PEREZ-GRACIA, J. L.; HAN, J-Y.; MOLINA, J.; KIM, J-H.; ARVIS, C. Dubos; AHN, M-J. A.; MAJEM, M.; FIDLER, M. J.; CASTRO JR., G. De; GARRIDO, M.; SHENTU, Y.; LUBINIECKI, G. M.; GARON, E. B. |
| 2016 | Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC | BARLESI, F.; GARON, E.; KIM, D-W.; FELIP, E.; HAN, J-Y.; KIM, J-H.; AHN, M-J. A.; FIDLER, M. J.; GUBENS, M. A.; CASTRO, G.; SURMONT, V.; LI, Q.; DEITZ, A. C.; LUBINIECKI, G.; HERBST, R. S. |
| 2016 | Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE | MOK, T.; SCHMID, P.; CASTRO JR., G. de; SYRIGOS, K.; MARTIN, C.; YAMAMOTO, N.; AREN, O.; ARRIETA, O.; GOTTFRIED, M.; JAZIEH, A. R.; RAMLAU, R.; TIMCHEVA, C.; TRANI, L. |
| 2016 | Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP) | RIECHELMANN, R.; SRIMUNINNIMIT, V.; KAVAN, P.; BARTOLOMEO, M. Di; MAIELLO, E.; CICIN, I.; KROENING, H.; GARCIA-ALFONSO, P.; CHAU, I.; FERNANDEZ-MARTOS, C.; TER-OVANESOV, M.; PEETERS, M.; PICARD, P.; BORDONARO, R. |
| 2016 | Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) | LINCK, R. D. M.; ASPRINO, P. F.; FREITAS, F. P.; KOYAMA, F. C.; GALANTE, P. A. F.; RIECHELMANN, R.; REIS, L. F. L.; COSTA, F. P.; HOFF, P. M.; CAMARGO, A. A.; SABBAGA, J. |
| 2016 | Profile of cancer patients who visit a specialized emergency room in Sao Paulo, Brazil | RAPOZO, M. M.; HATANAKA, V. M.; BERNARDES, M. C.; ALBUQUERQUE, G. M.; DIZ, M. D. P. E. |
| 2018 | Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type | GROSSI, F.; JASKIEWICZ, P.; PICHON, E.; CZYZEWICZ, G.; KOWALSKI, D. M.; CIUFFREDA, L.; GOMEZ, R. Garcia; CARUSO, S.; BARRERA, J. Bosch; MINH, C. Ta Thanh; GAUTIER, S.; HERVIEU, H.; HENRIET, S.; CASTRO JR., G. De |
| 2018 | Neoadjuvant chemotherapy and radical surgery versus chemorradiation for stage IB2, IIA2 e IIB cervical cancer: A randomized controlled trial | REIS FILHO, P. T. F.; ANDRADE, J. M.; BATISTA, M. P.; SOUSA, C. B.; OLIVEIRA, T. H. G. F.; ARRUDA, G. V.; OLIVEIRA, T. M. G.; GABRIELLI, F.; GENTA, M. L. N. D.; POVEDA, A. M.; DIZ, M. D. P. Estevez; REIS, F. J. Candido Dos |